Hints and tips:
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Drugmakers GSK and Boehringer Ingelheim are now rationing inhalers, according to Premier....
...Ingelheim sold its 16.4 per cent stake....
...Ingelheim, after it received approval....
...Another company, Boehringer Ingelheim of Germany, remains in patent litigation with AbbVie and has no plans for a European launch, despite its medicine being approved for sale in the EU....
...That would have been close to the multiple of 22 times operating earnings before usual deductions used to price Sanofi’s €21.8bn asset swap with Boehringer Ingelheim last year....
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...Addyi was first developed as an antidepressant in the 1990s by Boehringer Ingelheim, the German pharmaceuticals group, but failed to make it through clinical trials....
...A $2.6bn cash and stock takeover of Roxane (since renamed West-Ward Columbus) the US generic drugs unit of Germany’s Boehringer Ingelheim, was meant to change that. Initially, it did the opposite....
...Ingelheim in July....
...But, since then, it says: Hikma received new information from BI [Boehringer Ingelheim] in relation to Roxane’s financial performance during 2015, which the Hikma Board believes will also have an impact...
...Jordan-founded but UK-listed Hikma initially agreed to buy the business from Boehringer Ingelheim in July, declaring that the deal would transform its scale and position in the US....
...Hikma moved to calm investors’ nerves after its shares fell 15 per cent in response to news that a deal to buy US generic drug assets from Boehringer Ingelheim has been renegotiated because of lower than...
...The shares have been rocked by declining generics sales, downgrades to the potential earnings of Roxane, the business it agreed to buy from Boehringer Ingelheim in July, and a broad sell-off in global pharmaceutical...
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...In July last year, it agreed to pay $2.65bn in cash and shares for Roxane, a generics business owned by Germany’s Boehringer Ingelheim....
...Ingelheim....
...Roxane marked Hikma’s second deal with Boehringer Ingelheim in the past two years after the $300m acquisition of the German company’s Bedford Laboratories unit in 2014....
...Andreas Barner, chairman of Boehringer Ingelheim said: Boehringer Ingelheim Animal Health is and will stay strongly committed to bringing novel, innovation driven solutions to veterinarians and animal owners...
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...Sanofi last month completed a €22.8bn asset swap with Boehringer Ingelheim, which allowed the French group to trade its animal health unit and gain a new consumer-health focused business as well as a €4.7bn...
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...GlaxoSmithKline and Novartis swapped oncology and vaccine assets in 2015; on Tuesday, Sanofi and Boehringer Ingelheim said they were in talks about swapping their animal and consumer health divisions....
...Hikma Pharmaceuticals bounced off a one-month low on Wednesday, helped by speculation of a tie-up with German drugmaker Boehringer Ingelheim....
International Edition